- Number of Upgrades from Top-Ranked Analysts
- 5 (in the last 90 days)
- Consensus Rating
- Hold
- Rating Score
- 2.3
- Ratings Breakdown
- 5 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $5.87 (530.8% Upside)
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Read More
Recent Analyst Ratings